A large randomized trial of AbbVie Inc.’s Kaletra (lopinavir-ritonavir) has been found to have no benefits for patients hospitalized with COVID-19, despite early hopes for the HIV combination therapy.
The result are the third major finding of the adaptive RECOVERY trial led by the University of Oxford in the...







